Literature DB >> 25866279

DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944.

Clement Lin, Danzhou Yang1.   

Abstract

XR5944 is a potent anticancer drug with a novel DNA binding mode: DNA bisintercalationg with major groove binding. XR5944 can bind the estrogen response element (ERE) sequence to block ER-ERE binding and inhibit ERα activities, which may be useful for overcoming drug resistance to currently available antiestrogen treatments. This review discusses the progress relating to the structure and function studies of specific DNA recognition of XR5944. The sites of intercalation within a native promoter sequence appear to be different from the ideal binding site and are context- and sequence- dependent. The structural information may provide insights for rational design of improved EREspecific XR5944 derivatives, as well as of DNA bis-intercalators in general.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25866279      PMCID: PMC4772870          DOI: 10.2174/1568026615666150413155608

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  61 in total

Review 1.  Molecular recognition of DNA by small molecules.

Authors:  P B Dervan
Journal:  Bioorg Med Chem       Date:  2001-09       Impact factor: 3.641

Review 2.  Aromatase inhibitors for breast cancer in postmenopausal women.

Authors:  Susana M Campos
Journal:  Oncologist       Date:  2004

Review 3.  Estrogen carcinogenesis in breast cancer.

Authors:  James D Yager; Nancy E Davidson
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

4.  Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents.

Authors:  Nigel Vicker; Luke Burgess; Irina S Chuckowree; Rory Dodd; Adrian J Folkes; David J Hardick; Timothy C Hancox; Warren Miller; John Milton; Sukhjit Sohal; Shouming Wang; Stephen P Wren; Peter A Charlton; Wendy Dangerfield; Chris Liddle; Prakash Mistry; Alistair J Stewart; William A Denny
Journal:  J Med Chem       Date:  2002-01-31       Impact factor: 7.446

5.  In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II.

Authors:  Prakash Mistry; Alistair J Stewart; Wendy Dangerfield; Mark Baker; Chris Liddle; Douglas Bootle; Bettina Kofler; Deanne Laurie; William A Denny; Bruce Baguley; Peter A Charlton
Journal:  Anticancer Drugs       Date:  2002-01       Impact factor: 2.248

6.  Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.

Authors:  S A Gamage; J A Spicer; G J Finlay; A J Stewart; P Charlton; B C Baguley; W A Denny
Journal:  J Med Chem       Date:  2001-04-26       Impact factor: 7.446

Review 7.  Estrogen receptor interaction with estrogen response elements.

Authors:  C M Klinge
Journal:  Nucleic Acids Res       Date:  2001-07-15       Impact factor: 16.971

Review 8.  Dual topoisomerase I/II inhibitors in cancer therapy.

Authors:  William A Denny; Bruce C Baguley
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

9.  Biological characterization of MLN944: a potent DNA binding agent.

Authors:  Darshan S Sappal; A Kathleen McClendon; James A Fleming; Vala Thoroddsen; Kelly Connolly; Corinne Reimer; Ronald K Blackman; Christine E Bulawa; Neil Osheroff; Peter Charlton; Laura A Rudolph-Owen
Journal:  Mol Cancer Ther       Date:  2004-01       Impact factor: 6.261

Review 10.  Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs).

Authors:  Rachel Schiff; Gary C Chamness; Powel H Brown
Journal:  Breast Cancer Res       Date:  2003-07-28       Impact factor: 6.466

View more
  3 in total

Review 1.  An overview of recent advances in duplex DNA recognition by small molecules.

Authors:  Sayantan Bhaduri; Nihar Ranjan; Dev P Arya
Journal:  Beilstein J Org Chem       Date:  2018-05-16       Impact factor: 2.883

2.  Synthesis, Biological Activity and Preliminary in Silico ADMET Screening of Polyamine Conjugates with Bicyclic Systems.

Authors:  Marta Szumilak; Malgorzata Galdyszynska; Kamila Dominska; Irena I Bak-Sypien; Anna Merecz-Sadowska; Andrzej Stanczak; Boleslaw T Karwowski; Agnieszka W Piastowska-Ciesielska
Journal:  Molecules       Date:  2017-05-12       Impact factor: 4.411

Review 3.  Selective antagonism of cJun for cancer therapy.

Authors:  Andrew Brennan; James T Leech; Neil M Kad; Jody M Mason
Journal:  J Exp Clin Cancer Res       Date:  2020-09-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.